而在此前不久，锦波生物控股股东、实际控制人杨霞已将其持有的575.33万股股票转让给杭州久视，占 公司总股本的5%，共计14.03亿元。据了解，养生堂与杭州久视的实控人均为钟睒睒。 21世纪经济报道记者韩利明 近期，北交所"重组胶原蛋白第一股"锦波生物公告显示，拟向养生堂发行不超过717.56万股股份，占发 行前公司总股本的6.24%，发行价格为278.72元/股，募资总额不超过20亿元，用于人源化胶原蛋白FAST 数据库与产品开发平台项目等。该申请已获北交所受理。 据《福布斯中国内地富豪榜》，2024年钟睒睒凭借508亿美元身家成功蝉联中国内地首富；进入2025 年，《福布斯全球亿万富豪榜》显示，其在内地富豪中的排名落于张一鸣之后。 值得关注的是，锦波生物是其继万泰生物（603392）后，再次重资投入的生物技术领域企业。在这背 后，万泰生物作为曾经风光无限的国产HPV疫苗头部企业，自2023年起业绩出现持续下滑，这也使得市 场对钟睒睒此次新入局的锦波生物及背后的医美赛道更为关注。 从行业大环境来看，近年来我国医美市场需求呈现旺盛且多元的发展态势，上游产品技术的迭代创新与 现有产品适应症的不断扩展，持续丰富着 ...

Core Viewpoint - Baiaosaitu (Beijing) Pharmaceutical Technology Co., Ltd. is set to undergo its IPO review on September 24, 2025, after a two-year wait on the Sci-Tech Innovation Board, highlighting its progress in the biopharmaceutical sector and its innovative "Thousand Mice Ten Thousand Antibodies" program [1][4]. Group 1: Company Overview - Baiaosaitu was established in 2009 and operates as a preclinical CRO and biotechnology company, providing innovative animal models and drug development services based on its proprietary gene editing technology [1]. - The company has developed the RenMice platform, which allows for large-scale drug discovery targeting nearly a thousand potential drug targets [1]. Group 2: IPO Process and Financial Performance - The company was accepted for its Sci-Tech Innovation Board IPO on June 20, 2023, and has undergone two rounds of inquiries prior to the upcoming review [4]. - Financial data shows that Baiaosaitu's revenue increased from approximately 534 million yuan in 2022 to 980 million yuan in 2024, with a turnaround to a net profit of approximately 33.54 million yuan in 2024 after previous losses [5]. - In the first half of 2023, the company achieved a revenue of 621 million yuan, a 51.27% increase year-on-year, and reported a net profit of approximately 47.99 million yuan, indicating a successful recovery from losses [6]. Group 3: Research and Development Challenges - The company has experienced a significant reduction in its R&D personnel, with the number of dedicated R&D staff dropping from 58 in 2022 to just 5 in 2024, raising concerns about its innovation capacity [7]. - Governance issues are also present, as the major shareholders, who are a married couple, control over 27% of the voting rights, which may impact decision-making processes [7]. Group 4: Fundraising and Strategic Direction - Baiaosaitu has reduced its planned fundraising amount from 1.893 billion yuan to 1.185 billion yuan for its IPO, focusing on early drug development services, antibody drug research, and clinical projects [7][8]. - The company asserts that this reduction in fundraising will not alter its strategic direction, as the core projects will still revolve around its main business and technology platforms [8].

Market Overview - Global financial markets exhibit complex and divergent trends, with the US market continuing to reach new highs driven by strong performance in technology and small-cap stocks [1] - The S&P 500 and Russell 2000 indices show notable gains, while the Dow Jones index experiences a slight increase, supported by robust corporate earnings and positive developments in the AI sector [1][3] - In contrast, European markets show weakness, with the UK FTSE 100 index slightly up, while the German DAX and French CAC 40 indices both decline, reflecting concerns over economic growth and policy uncertainty in the region [1][3] Commodity Performance - Gold prices have significantly risen, indicating strong demand, while WTI crude oil prices are under pressure due to expectations of increased supply [1][4] - The reopening of a major pipeline in Iraq has heightened supply concerns, contributing to a decline in oil prices [4] Key Indices and Movements - The S&P 500 index increased by 0.44% to 6,693.75, while the Dow Jones rose by 0.14% to 46,381.54 [4] - The Nasdaq 100 index saw a rise of 0.55% to 22,788.98, and the Russell 2000 index increased by 0.60% to 2,463.34 [4] - European indices such as the DAX and CAC 40 experienced declines of 0.48% and 0.30%, respectively, indicating a bearish sentiment in the region [4] Investor Sentiment - Overall, investors maintain a defensive stance with limited risk appetite, as evidenced by the mixed performance across global markets [3] - The focus for upcoming trading days will be on signals from the Federal Reserve regarding monetary policy and key inflation data [3]

Group 1: Market Adjustment Overview - In September 2025, 20 stocks were added to and 20 stocks were removed from the Hong Kong Stock Connect, with 19 of the new additions matching prior predictions[9] - The average market capitalization of the stocks added was 246.5 billion HKD, with the highest being 445.6 billion HKD for Yaojie Ankang-B[7] - Prior to the adjustment, the added stocks experienced an average price increase of 16.30% over the previous month, 4.54% over the previous week, and 5.76% on the last trading day[10] Group 2: Stock Performance Analysis - The average price change on the adjustment day was -2.10%, followed by an average increase of 16.07% in the week after the adjustment[10] - Stocks added to the Connect outperformed their respective industry indices prior to the adjustment, with average relative returns of 10.84%, 1.94%, and 3.19% over the previous month, week, and day respectively[13] - The average relative return on the adjustment day was -3.02%, with a subsequent average return of 13.49% in the following week[13] Group 3: Future Projections - For March 2026, 17 stocks are projected to meet the Hong Kong Stock Connect eligibility criteria, with the lowest estimated market capitalization being 89.1 billion HKD[29] - An additional 29 stocks are close to meeting the criteria, with market capitalizations ranking between the 94th and 96th percentiles[31] - The analysis assumes that trading data from September to December will maintain August's average levels, which may affect future eligibility[29][31] Group 4: Risk Factors - Market capitalization ranking fluctuations pose a risk, as the assessment for March 2026 will consider a full 12-month period, potentially impacting the results[35] - Changes in liquidity ratios could affect stock eligibility, especially if significant changes in shareholding occur[35] - Regulatory changes regarding the inclusion criteria for the Hong Kong Stock Connect may also impact future adjustments[35]

来源：滚动播报 减肥药制造商Metsera飙升 58.9%，该公司宣布将被辉瑞以 49 亿美元现金收购，辉瑞涨1.0%。经纪业巨 头Compass计划以 16 亿美元全股票交易收购竞争对手Anywhere公司，Anywhere涨55.5%，而Compass下 跌7.9%。Sarepta Therapeutics涨6.8%，BMO将这家生物技术公司的股票评级上调至 "跑赢大盘"，并预测 其股价将翻倍以上。文远知行涨2.3%，将在新加坡推出自动驾驶出租车服务。 ...

Focus Review - The low-altitude economy is gaining attention, with Micro Differential Intelligence completing nearly 200 million RMB in Pre-A and Pre-A+ financing [4][14]. - The biopharmaceutical sector remains a core focus, with Huakan Bio announcing a successful B+ round financing of several hundred million RMB [26]. - Investment in the internet sector is highlighted by Baidu's continued investment in AI, with Shengshu Technology completing a new round of A financing worth several hundred million RMB [39]. New Consumption - Qilin Yi, a Chinese fast-food innovation company, secured 18.6 million RMB in A round financing led by Zhisheng Capital [7]. Hard Technology - Lingming Photon completed C3 round financing, receiving nearly 100 million RMB from Zhejiang provincial state-owned platforms [9]. - Starfire Space completed 55 million RMB in angel round financing, led by Jingsha Capital [10]. - Haide Hydrogen Energy announced a new strategic financing round, with investments from NIO Capital and other institutions [11]. Health Sector - Enrui Kainuo completed over 200 million RMB in A round financing, led by Shenzhen Capital Group and others [27]. - Medical technology company Painova announced the completion of its B round financing, led by Jifeng Asia Investment [25]. Internet/Enterprise Services - Teable, a new player in the AI Agent sector, announced the completion of several million USD in angel round financing [36]. - Weimeng Group secured 200 million USD in financing from Infini Capital [37].

Core Insights - The breakthrough in artificial starch synthesis through synthetic biology allows for starch production without reliance on agricultural resources such as land and freshwater, potentially reshaping the landscape of biological manufacturing and agricultural production [1][3]. Group 1: Synthetic Biology Overview - Synthetic biology, originating from the term coined by French chemist Stéphane Leduc in 1911, is an interdisciplinary field that combines biology, genomics, engineering, and informatics to design biological systems and even create new life [3]. - The artificial synthesis of starch represents a milestone in synthetic biology, moving from natural photosynthesis processes to engineered methods that utilize carbon dioxide, water, and hydrogen as raw materials [3][4]. Group 2: Technological Advancements - The research team led by Ma Yanhe successfully identified the optimal pathway from 6,568 biochemical reactions, addressing challenges in thermodynamic matching and metabolic flow balance to synthesize starch [4]. - The latest version of the artificial starch synthesis pathway has improved energy conversion efficiency by 3.5 times and reduced synthesis time from 2-3 months to just a few days, indicating a significant advancement in industrial starch production capabilities [6]. Group 3: Market Potential - The global synthetic biology market has grown from $5.3 billion in 2018 to over $17 billion in 2023, with an average annual growth rate of 27%, and is projected to reach nearly $50 billion by 2028 [8]. - The integration of artificial intelligence in synthetic biology is enhancing the rational design process, expanding applications to complex molecules such as sucrose, hexose, and biodegradable materials, providing new solutions for the food, energy, and pharmaceutical industries [6]. Group 4: Event and Collaboration - The "Good Hope Science Salon" event, co-hosted by various organizations, aims to create a platform for impactful interdisciplinary collaboration and exchange in the field of synthetic biology [10]. - Over 100 experts, scholars, and industry leaders participated in discussions about technological advancements and commercialization prospects in synthetic biology [6].

近年来，河南省漯河市聚焦高质量供给、高水平转化，推动产业创新强基固本，打通堵点难点。上半 年，全市地区生产总值961亿元，增长7.3%，增速为河南省第一。 漯河市推动食品技术、生物技术与信息技术协同攻关，培育工程化食品和健康食品，布局"益生菌+""塔 格糖+""天然色素+"食品新赛道，打造具有全国影响力的古风食品IP，建设覆盖传统经典、健康升级、 智能制造的多样化产业集群，推动食品产业成为经典产业、朝阳产业、幸福产业。目前，全市企业主导 或参与制修订国际标准5项、国家和行业标准近百项。 针对科创企业技术投入大、转化周期长等特点，漯河市设立5000万元科创风险补偿金，推行研发费用损 失险等科技保险，整合国有资本设立授信资金，撬动社会资本设立产业基金，贯通企业研发至量产全链 条。 漯河市委书记秦保强表示，将以科研成果转化、新质生产力项目落地为导向，构建科技创新、产业创 新、金融创新"三新"融合生态。 (责任编辑：王擎宇) 围绕打造引人用人良好生态，漯河市创新"柔性引进科学家、刚性引育团队"机制，发布高层次创新人 才"六可选"服务保障措施，汇聚25名院士、147支科学家团队，形成了院士牵头的中原食品实验室、氟 硅新 ...

来源：市场资讯 （来源：美股情报站） 近期，生物科技巨头安进公司的股价表现引人注目。9月19日，该公司股价上涨了3.47%，连续三天保 持增长，累计增幅达4.51%。这反映出市场对安进最新动态的积极评价，以及投资者乐观的情绪。 安进公司于8月6日发布了2025财年的中期财报，数据显示公司于2025年上半年实现收入173.28亿美元， 同比增长9.43%。令人瞩目的是，净利润增长至31.62亿美元，较去年同期激增399.53%。如此显著的盈 利增长表明公司在战略执行和市场扩展方面取得了不俗的成就，也为股价提供了支持。 安进公司成立于1980年，并于1987年迁至特拉华州。作为全球领先的独立生物技术公司，安进致力于发 现、开发和提供创新药物，以解决全球一些最为严峻的医疗需求。公司在过去40多年中，不仅开创了生 物技术产业，还在不断寻求能够改善人类生活的解决方案，同时努力减轻疾病带来的社会和经济负担。 在分析安进股价变化的背后因素时，公司财报显然是一个关键推动力。此外，生物技术行业的整体趋势 也是不可忽视的因素。随着全球对创新医药需求的增长，生物科技领域的投资吸引力不断增强。安进凭 借其技术优势和市场领先地位，有望 ...

每年，全球精准肿瘤治疗领域的目光都会聚焦在行业的研发日。 近日，IDEAYA Biosciences 举办十周年研发日（R&D Day），披露了多项研发进展、战略规划和技 术平台。作为一家在精准肿瘤治疗领域快速成长的美国生物技术公司，IDEAYA此次除了自有管线最 新成果，还重点介绍了两个引进的项目：从中国公司恒瑞医药引进的DLL3 抗体药物偶联物 （ADC）项目 IDE849，和从百奥赛图引进的B7H3/PTK7双特异性抗体偶联药物（bsADC）项目 IDE034。 在当今市场都聚焦IO抗体+ADC的热潮背景下，IDEAYA创新性聚焦和探索小分子+ADC联用策略， 旨在探索PARG抑制剂联合新一代ADC所蕴含的"王炸"潜力。 01 从小分子到大分子的叠加 为什么以小分子见长的 IDEAYA，要跑去玩"大分子"？ PARG抑制剂是IDEAYA开发的首个临床候选药物，属于DNA 损伤修复（DDR）通路中的新型合成 致死靶点。合成致死策略是通过靶向肿瘤细胞中已存在的 DNA 修复缺陷，让肿瘤自我"爆炸"。这是 精准肿瘤治疗的重要方向，也是IDEAYA的战略核心。而合成致死抑制剂的差异化潜力在于联用。近 年来，研究 ...